ProNAi Therapeutics (NASDAQ:DNAI) On August 12, 2016 ProNAi Therapeutics had finally completely dropped its PNT2258 drug from its pipeline. It has been a long tough road for the company, who reported its failed phase 2 results at the ASCO meeting held in June. The study reported was known as the “Wolverine” trial, and it treated … Read more
Seres Therapeutics (NASDAQ:MCRB) On Friday, Seres Therapeutics stock plummeted by 70% after the company reported that it had failed mid-stage trial in patients with Clostridium difficile infection or C. diff. The company has a big pipeline, but the problem is that the study that failed was the lead drug candidate. Thus, the reason why the … Read more
StemCells Inc. (NASDAQ:STEM) On Tuesday May 31, 2016 shares of Stemcells fell by more than 83% after the company announced that it would completely stop its phase 2 Pathway study. The phase 2 study used Stem’s HuCNS-SC human neural stem cells to treat spinal cord injury. This was a huge shock for investors, because the … Read more
Rxi Pharmaceuticals (NASDAQ:RXII) On Tuesday April 19, 2016 Rxi Pharmaceuticals announced that it would present pre-clinical data at a medical conference, known as 2016 ARVO Conference. ARVO stands for Association for Research in Vision and Ophthalmology. The pre-clinical data to be presented will be the company’s drug in corneal scarring. In order to prevent injury … Read more
BioCryst Pharmaceuticals (NASDAQ: BCRX) On February 8, 2016 shares of BioCryst Pharmaceuticals fell by more than 71% after the company had announced that it had failed a phase 2 trial. The phase 2 trial known as the OPuS-2 trial recruited a total of 108 patients with Hereditary Angiodema — HAE. HAE is a rare genetic … Read more
Amgen, Inc. (NASDAQ:AMGN) On October 28, 2015 Amgen had announced that it had received FDA approval for its skin cancer drug known as IMLYGIC. This drug is an injection type drug that helps boost the immune system to fight off and kill cancerous skin cells. This therapy only treats Melanoma — skin cancer– but does … Read more
Bluebird Bio (NASDAQ:BLUE) On October 19, 2015 shares of Bluebird Bio fell approximately 4% after the company announced that one patient on its old generation gene therapy had required two blood transfusions due to anemia. One thing to keep in mind was that this patient was blood transfusion free for 7 years and that’s why … Read more
Immunogen (NASDAQ:IMGN) Shares of Immunogen soared as much as 68% on June 1, 2015 after the company reported positive results in patients with platinum-resistant ovarian cancer. There are about 21,290 cases of women who get ovarian cancer in the United States each year. The problem is that a lot of these patients that take chemotherapy … Read more